 | Up a level |
Lesche, Dorothea; Sigurdardottir, Vilborg; Leichtle, Alexander Benedikt; Nakas, Christos T.; Christians, Uwe; Englberger, Lars; Fiedler, Georg Martin; Largiadèr, Carlo Rodolfo; Mohacsi, Paul; Sistonen, Johanna (2018). Targeted and global pharmacometabolomics in everolimus-based immunosuppression: association of co-medication and lysophosphatidylcholines with dose requirement. Metabolomics, 14(1), p. 3. Springer 10.1007/s11306-017-1294-8
Lesche, Dorothea; Sigurdardottir, Vilborg; Setoud, Raschid; Englberger, Lars; Fiedler, Georg M.; Largiadèr, Carlo R.; Mohacsi, Paul; Sistonen, Johanna (2015). Influence of CYP3A5 genetic variation on everolimus maintenance dosing after cardiac transplantation. Clinical transplantation, 29(12), pp. 1213-1220. Wiley-Blackwell 10.1111/ctr.12653
Kummer, Dominic; Fröhlich, Tanja; Joerger, Markus; Aebi, Stefan; Sistonen, Johanna; Amstutz, Ursula; Largiadèr, Carlo Rodolfo (2015). Dihydropyrimidinase and β-ureidopropionase gene variation and severe fluoropyrimidine-related toxicity. Pharmacogenomics, 16(12), pp. 1367-1377. Future Medicine 10.2217/pgs.15.81
Amstutz, Ursula; Offer, Steven M; Sistonen, Johanna; Joerger, Markus; Diasio, Robert B; Largiadèr, Carlo Rodolfo (2015). Polymorphisms in MIR27A Associated with Early-Onset Toxicity in Fluoropyrimidine-Based Chemotherapy. Clinical cancer research, 21(9), pp. 2038-2044. American Association for Cancer Research 10.1158/1078-0432.CCR-14-2817
Lesche, Dorothea; Sigurdardottir, Vilborg; Setoud, Raschid; Oberhänsli, Markus; Carrel, Thierry; Fiedler, Georg M; Largiadèr, Carlo Rodolfo; Mohacsi, Paul; Sistonen, Johanna (2014). CYP3A5*3 and POR*28 genetic variants influence the required dose of tacrolimus in heart transplant recipients. Therapeutic drug monitoring, 36(6), pp. 710-715. Lippincott Williams & Wilkins 10.1097/FTD.0000000000000080
Sistonen, Johanna; Büchel, Barbara; Fröhlich, Tanja; Kummer, Dominic; Fontana, Stefano; Joerger, Markus; van Kuilenburg, André B P; Largiadèr, Carlo Rodolfo (2014). Predicting 5-fluorouracil toxicity: DPD genotype and 5,6-dihydrouracil:uracil ratio. Pharmacogenomics, 15(13), pp. 1653-1666. Future Medicine 10.2217/pgs.14.126
Aminkeng, F.; Ross, C. J. D.; Rassekh, S. R.; Brunham, L. R.; Sistonen, Johanna; Dube, M.-P.; Ibrahim, M.; Nyambo, T. B.; Omar, S. A.; Froment, A.; Bodo, J.-M.; Tishkoff, S.; Carleton, B. C.; Hayden, M. R. (2014). Higher frequency of genetic variants conferring increased risk for ADRs for commonly used drugs treating cancer, AIDS and tuberculosis in persons of African descent. Pharmacogenomics journal, 14(2), pp. 160-170. Nature Publishing Group 10.1038/tpj.2013.13
Madadi, Parvaz; Sistonen, Johanna; Silverman, Gregory; Gladdy, Rebecca; Ross, Colin J.; Carleton, Bruce C.; Carvalho, Jose C.; Hayden, Michael R.; Koren, Gideon (2013). Life-threatening adverse events following therapeutic opioid administration in adults: Is pharmacogenetic analysis useful? Pain research and management, 18(3), pp. 133-136. Pulsus Group Inc.
Büchel, Barbara; Sistonen, Johanna; Joerger, Markus; Aebi, Yolanda; Schürch, Stefan; Largiadèr, Carlo Rodolfo (2013). Comparative evaluation of the My5-FU™ immunoassay and LC-MS/MS in monitoring the 5-fluorouracil plasma levels in cancer patients. Clinical chemistry and laboratory medicine, 51(8), pp. 1681-1688. De Gruyter 10.1515/cclm-2012-0641
Sistonen, Johanna; Smith, Chingying; Fu, Yung-Kang; Largiadèr, Carlo R (2012). A new DPYD genotyping assay for improving the safety of 5-fluorouracil therapy. Clinica chimica acta, 414, pp. 109-111. Amsterdam: Elsevier 10.1016/j.cca.2012.08.015
Khetani, Justin D; Madadi, Parvaz; Sommer, Doron D; Reddy, Desigen; Sistonen, Johanna; Ross, Colin J D; Carleton, Bruce C; Hayden, Michael R; Koren, Gideon (2012). Apnea and oxygen desaturations in children treated with opioids after adenotonsillectomy for obstructive sleep apnea syndrome: a prospective pilot study. Pediatric drugs, 14(6), pp. 411-5. Heidelberg: Springer 10.2165/11633570-000000000-00000
